Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1.

Marcinkowski B, Stevanović S, Helman SR, Norberg SM, Serna C, Jin B, Gkitsas N, Kadakia T, Warner A, Davis JL, Rooper L, Hinrichs CS.

J Immunother Cancer. 2019 Aug 28;7(1):229. doi: 10.1186/s40425-019-0678-x.

2.

T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.

Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS.

J Clin Oncol. 2019 Aug 13:JCO1802424. doi: 10.1200/JCO.18.02424. [Epub ahead of print]

PMID:
31408414
3.

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.

Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS.

J Immunother Cancer. 2019 May 3;7(1):119. doi: 10.1186/s40425-019-0603-3.

4.

Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.

Helman SR, Stevanovic S, Campbell TE, Kwong MLM, Doran SL, Faquin WC, Hinrichs CS.

JAMA Netw Open. 2018 Jul 6;1(3):e180706. doi: 10.1001/jamanetworkopen.2018.0706.

5.

A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.

Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS.

Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722. Epub 2018 Dec 5.

6.

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS.

JCI Insight. 2018 Apr 19;3(8). pii: 99488. doi: 10.1172/jci.insight.99488. eCollection 2018 Apr 19.

7.

Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy.

Hinrichs CS.

J Clin Invest. 2018 Apr 2;128(4):1261-1263. doi: 10.1172/JCI120386. Epub 2018 Mar 12.

8.

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.

Jin J, Gkitsas N, Fellowes VS, Ren J, Feldman SA, Hinrichs CS, Stroncek DF, Highfill SL.

J Transl Med. 2018 Jan 24;16(1):13. doi: 10.1186/s12967-018-1384-z.

9.

Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.

Kang Z, Stevanović S, Hinrichs CS, Cao L.

Clin Cancer Res. 2017 Nov 15;23(22):6856-6862. doi: 10.1158/1078-0432.CCR-17-1553. Epub 2017 Sep 12.

10.

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.

Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS.

Science. 2017 Apr 14;356(6334):200-205. doi: 10.1126/science.aak9510.

11.

Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.

Hinrichs CS.

Clin Cancer Res. 2016 Apr 1;22(7):1559-64. doi: 10.1158/1078-0432.CCR-15-1294. Review.

12.

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.

Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS.

Clin Cancer Res. 2015 Oct 1;21(19):4431-9. doi: 10.1158/1078-0432.CCR-14-3341.

13.

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS.

J Clin Oncol. 2015 May 10;33(14):1543-50. doi: 10.1200/JCO.2014.58.9093. Epub 2015 Mar 30.

14.

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.

Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.

15.

Exploiting the curative potential of adoptive T-cell therapy for cancer.

Hinrichs CS, Rosenberg SA.

Immunol Rev. 2014 Jan;257(1):56-71. doi: 10.1111/imr.12132. Review.

16.

Reassessing target antigens for adoptive T-cell therapy.

Hinrichs CS, Restifo NP.

Nat Biotechnol. 2013 Nov;31(11):999-1008. doi: 10.1038/nbt.2725. Epub 2013 Oct 20. Review.

17.

Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.

Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA.

J Immunol. 2013 Sep 1;191(5):2217-25. doi: 10.4049/jimmunol.1300538. Epub 2013 Jul 31.

18.

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.

Clin Cancer Res. 2011 Aug 15;17(16):5343-52. doi: 10.1158/1078-0432.CCR-11-0503. Epub 2011 Jul 7.

19.

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.

J Immunother. 2011 May;34(4):343-52. doi: 10.1097/CJI.0b013e3182187600.

20.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.

Blood. 2011 Jan 20;117(3):808-14. doi: 10.1182/blood-2010-05-286286. Epub 2010 Oct 22.

21.

A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.

Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA.

Cancer Res. 2010 Apr 15;70(8):3027-33. doi: 10.1158/0008-5472.CAN-09-2824.

22.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.

23.

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.

Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP.

Nat Med. 2009 Jul;15(7):808-13. doi: 10.1038/nm.1982. Epub 2009 Jun 14.

24.

Type 17 CD8+ T cells display enhanced antitumor immunity.

Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP.

Blood. 2009 Jul 16;114(3):596-9. doi: 10.1182/blood-2009-02-203935. Epub 2009 May 26.

25.

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP.

Blood. 2008 Dec 1;112(12):4746-54. doi: 10.1182/blood-2008-07-169797. Epub 2008 Sep 17.

26.

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.

Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ Jr, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8061-6. doi: 10.1073/pnas.0710929105. Epub 2008 Jun 3.

27.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.

Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.

28.

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP.

Blood. 2008 Jun 1;111(11):5326-33. doi: 10.1182/blood-2007-09-113050. Epub 2008 Feb 14.

29.

Toll-like receptors in tumor immunotherapy.

Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5280-9. Review.

30.

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP.

J Clin Invest. 2007 Aug;117(8):2197-204. Erratum in: J Clin Invest. 2007 Oct;117(10):3140.

31.

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.

Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Klebanoff CA, Tagaya Y, Restifo NP.

J Immunol. 2006 May 1;176(9):5255-66. Erratum in: J Immunol. 2006 Jun 15;176(12):7788. Heinrichs, Christian [corrected to Hinrichs, Christian S].

32.

Programming CD8+ T cells for effective immunotherapy.

Hinrichs CS, Gattinoni L, Restifo NP.

Curr Opin Immunol. 2006 Jun;18(3):363-70. Epub 2006 Apr 17. Review.

33.

Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.

Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP.

J Immunother. 2005 Nov-Dec;28(6):517-24.

34.

Esophageal cancer.

Hinrichs CS, van Way CW 3rd.

Curr Surg. 2002 Jan-Feb;59(1):12-7. No abstract available.

PMID:
16093098
35.

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ.

J Exp Med. 2005 Jan 3;201(1):139-48.

36.

Lymphedema secondary to postmastectomy radiation: incidence and risk factors.

Hinrichs CS, Watroba NL, Rezaishiraz H, Giese W, Hurd T, Fassl KA, Edge SB.

Ann Surg Oncol. 2004 Jun;11(6):573-80.

PMID:
15172932
37.

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.

Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP.

J Leukoc Biol. 2004 Aug;76(2):333-7. Epub 2004 May 20.

38.

The effectiveness of complete decongestive physiotherapy for the treatment of lymphedema following groin dissection for melanoma.

Hinrichs CS, Gibbs JF, Driscoll D, Kepner JL, Wilkinson NW, Edge SB, Fassl KA, Muir R, Kraybill WG.

J Surg Oncol. 2004 Mar 15;85(4):187-92.

PMID:
14991874
39.

Electrosurgery 201: basic electrical principles.

Van Way CW, Hinrichs CS.

Curr Surg. 2000 May 1;57(3):261-264. No abstract available.

PMID:
10930624

Supplemental Content

Loading ...
Support Center